Léčba erlotinibem nemocných s nemalobuněčnými karcinomy plic - efekt snížené dávky při závažných nežádoucích účincích

Warning

This publication doesn't include Faculty of Sports Studies. It includes Faculty of Medicine. Official publication website can be found on muni.cz.

Title in English	Erlotinib therapy of patients with NSCLC - dose reduction in patients with severe adverse reactions
Authors	PEŠEK Miloš KREJČÍ Jana SKŘIČKOVÁ Jana ZATLOUKAL Petr KOLEK Vítězslav SALAJKA František KOUBKOVÁ Leona SIXTOVÁ Dimka PETRUŽELKA Luboš ROUBEC Jaromír VYZULA Rostislav PAVLÍK Tomáš MINÁRIK M.
Year of publication	2010
Type	Article in Proceedings
Conference	XXXIV. Brněnské onkologické dny
MU Faculty or unit	Faculty of Medicine
Citation
Field	Pneumology
Keywords	erlotinib; NSCLC; dose reduction; adverse reaction
Description	This contribution to the conference was dedicated to the analysis of dose reduction effect in patients treated for NSCLC with erlotinib who suffered from severe adverse reactions.
Related projects:	Environment - carcinogenesis - oncology